Research programme: Anticancer therapeutics - Ildong PharmaceuticalsAlternative Names: ID 6201; ID 6302
Latest Information Update: 19 Oct 2015
At a glance
- Originator Ildong Pharmaceutical
- Class Sulfonylureas
- Mechanism of Action Heat-shock protein inhibitors; Protein kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 19 Oct 2015 Preclinical trials in Cancer in South Korea (unspecified route)
- 19 Oct 2015 Ildong Pharmaceuticals has patent protection for anticancer drugs in Korea